Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential High Dose MVAC Followed by Gemcitabine Plus Cisplatin in Bladder Cancer
NCT00635726Phase 2Terminated
- Sponsor
- Hellenic Oncology Research Group
- Start
- Feb 2008
- Primary completion
- Feb 2013
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of methotrexate, vinblastine, pegylated liposomal doxorubicin, Cisplatin micelle injection (HA132), gemcitabine in bladder cancer, sponsored by Hellenic Oncology Research Group. Started Feb 2008; status: terminated.
02
Drugs
methotrexatevinblastinepegylated liposomal doxorubicinCisplatin micelle injection (HA132)gemcitabine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00635726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00635726.